



JAN 1-643
3/9/00
#8

PATENT
Docket No. 265036600070

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : R. Yanagimachi
Serial No. : 09/371,648 JAN 11 2000
Filed : August 10, 1999 TECH CENTER 1600/2900
For : **MAMMALIAN TRANSGENESIS BY
INTRACYTOPLASMIC SPERM
INJECTION**
Group Art Unit : 1643
Examiner : unknown

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner
for Patents
Washington, D.C. 20231

Sir:

This application claims the benefit of U.S. Provisional Patent Applications, Serial No. 60/096,078, filed August 11, 1998, and Serial No. 60/133,970, filed May 13, 1999.

Pursuant to the guidelines for Information Disclosure Statements set forth in 37 CFR §§ 1.97-1.98 and MPEP § 609, applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty of disclosure in accordance with 37 CFR § 1.56.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date indicated below.

Alan J. Klopp, Ph.D.

Name

1/6/00
Date

Signature

A list of patent(s) and/or publications not already submitted in previous disclosures is set forth on the attached PTOL-1449. A copy of each item listed is supplied herewith. The items were cited in a communication from a foreign patent office in a counterpart foreign application, namely, an International Search Report in a counterpart PCT application. A copy of the International Search Report is provided herewith for the Examiner's convenience.

In accordance with 37 CFR § 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56.

In accordance with 37 CFR § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR § 1.56 exists.

Any additional fees required for the proper filing of this Supplemental Information Disclosure Statement should be withdrawn from the Jones, Day, Reavis & Pogue Deposit Account No. 10-1202, reference 265036-600-070.

Respectfully submitted,

JONES, DAY, REAVIS & POGUE



Barbara E. Arndt, Ph.D.
Reg. No. 37,768

North Point
901 Lakeside Avenue
Cleveland, Ohio 44114
(216) 586-7575